Show simple item record

dc.contributor.authorHesse, Christina
dc.contributor.authorGinter, Wiebke
dc.contributor.authorFörg, Theresa
dc.contributor.authorMayer, Christian T
dc.contributor.authorBaru, Abdul Mannan
dc.contributor.authorArnold-Schrauf, Catharina
dc.contributor.authorUnger, Wendy W J
dc.contributor.authorKalay, Hakan
dc.contributor.authorvan Kooyk, Yvette
dc.contributor.authorBerod, Luciana
dc.contributor.authorSparwasser, Tim
dc.date.accessioned2013-11-21T09:48:03Zen
dc.date.available2013-11-21T09:48:03Zen
dc.date.issued2013-10en
dc.identifier.citationIn vivo targeting of human DC-SIGN drastically enhances CD8⁺ T-cell-mediated protective immunity. 2013, 43 (10):2543-53 Eur. J. Immunol.en
dc.identifier.issn1521-4141en
dc.identifier.pmid23784881en
dc.identifier.doi10.1002/eji.201343429en
dc.identifier.urihttp://hdl.handle.net/10033/305604en
dc.description.abstractVaccination is one of the oldest yet still most effective methods to prevent infectious diseases. However, eradication of intracellular pathogens and treatment of certain diseases like cancer requiring efficient cytotoxic immune responses remain a medical challenge. In mice, a successful approach to induce strong cytotoxic CD8⁺ T-cell (CTL) reactions is to target antigens to DCs using specific antibodies against surface receptors in combination with adjuvants. A major drawback for translating this strategy into one for the clinic is the lack of analogous targets in human DCs. DC-SIGN (DC-specific-ICAM3-grabbing-nonintegrin/CD209) is a C-type lectin receptor with potent endocytic capacity and a highly restricted expression on human immature DCs. Therefore, DC-SIGN represents an ideal candidate for DC targeting. Using transgenic mice that express human DC-SIGN under the control of the murine CD11c promoter (hSIGN mice), we explored the efficacy of anti-DC-SIGN antibodies to target antigens to DCs and induce protective immune responses in vivo. We show that anti-DC-SIGN antibodies conjugated to OVA induced strong and persistent antigen-specific CD4⁺ and CD8⁺ T-cell responses, which efficiently protected from infection with OVA-expressing Listeria monocytogenes. Thus, we propose DC targeting via DC-SIGN as a promising strategy for novel vaccination protocols against intracellular pathogens.
dc.language.isoenen
dc.rightsArchived with thanks to European journal of immunologyen
dc.titleIn vivo targeting of human DC-SIGN drastically enhances CD8⁺ T-cell-mediated protective immunity.en
dc.typeArticleen
dc.contributor.departmentInstitute of Infection Immunology, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hannover (MHH) and the Helmholtz Centre for Infection Research (HZI), Hannover, Germany.en
dc.identifier.journalEuropean journal of immunologyen
refterms.dateFOA2014-04-15T00:00:00Z
html.description.abstractVaccination is one of the oldest yet still most effective methods to prevent infectious diseases. However, eradication of intracellular pathogens and treatment of certain diseases like cancer requiring efficient cytotoxic immune responses remain a medical challenge. In mice, a successful approach to induce strong cytotoxic CD8⁺ T-cell (CTL) reactions is to target antigens to DCs using specific antibodies against surface receptors in combination with adjuvants. A major drawback for translating this strategy into one for the clinic is the lack of analogous targets in human DCs. DC-SIGN (DC-specific-ICAM3-grabbing-nonintegrin/CD209) is a C-type lectin receptor with potent endocytic capacity and a highly restricted expression on human immature DCs. Therefore, DC-SIGN represents an ideal candidate for DC targeting. Using transgenic mice that express human DC-SIGN under the control of the murine CD11c promoter (hSIGN mice), we explored the efficacy of anti-DC-SIGN antibodies to target antigens to DCs and induce protective immune responses in vivo. We show that anti-DC-SIGN antibodies conjugated to OVA induced strong and persistent antigen-specific CD4⁺ and CD8⁺ T-cell responses, which efficiently protected from infection with OVA-expressing Listeria monocytogenes. Thus, we propose DC targeting via DC-SIGN as a promising strategy for novel vaccination protocols against intracellular pathogens.


Files in this item

Thumbnail
Name:
Hesse et al_final.pdf
Size:
595.3Kb
Format:
PDF
Description:
original mnuscript
Thumbnail
Name:
Final_Supp_Info.pdf
Size:
3.263Mb
Format:
PDF
Description:
supplemental materials

This item appears in the following Collection(s)

Show simple item record